Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin – propensity score matching study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin – propensity score matching study ; volume:24 ; number:1 ; day:13 ; month:12 ; year:2023 ; pages:1-9 ; date:12.2023
BMC pharmacology & toxicology ; 24, Heft 1 (13.12.2023), 1-9, 12.2023
- Urheber
-
Ramos-Isaza, Estefan
Tuta-Quintero, Eduardo
Bastidas-Goyes, Alirio
Diaz-Quijano, Diana
Aponte-Murcia, Carolina
Espitia-Angel, Julian
Pinto-Beltran, Daniel
Rincón-Hernández, Johan
Sánchez-Cuellar, Juan
Pérez-Bueno, Jesus
Giraldo-Cadavid, Luis F.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40360-023-00712-8
- URN
-
urn:nbn:de:101:1-2024022810293377415396
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ramos-Isaza, Estefan
- Tuta-Quintero, Eduardo
- Bastidas-Goyes, Alirio
- Diaz-Quijano, Diana
- Aponte-Murcia, Carolina
- Espitia-Angel, Julian
- Pinto-Beltran, Daniel
- Rincón-Hernández, Johan
- Sánchez-Cuellar, Juan
- Pérez-Bueno, Jesus
- Giraldo-Cadavid, Luis F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study
Rivaroxaban versus warfarin for the management of left ventricle thrombus
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease
Rivaroxaban for the treatment of cerebral venous thrombosis
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study
Rivaroxaban versus warfarin for the management of left ventricle thrombus
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease
Rivaroxaban for the treatment of cerebral venous thrombosis
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study
Rivaroxaban versus warfarin for the management of left ventricle thrombus
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism in African American patients: a retrospective cohort analysis
The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease
Rivaroxaban for the treatment of cerebral venous thrombosis
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban